Ga-68 Pentixafor PET/CT in multiple myeloma and its correlation with clinical parameters – institutional pilot study

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Objective: This study evaluates the role of Ga-68 Pentixafor PET/CT in staging and follow-up of multiple myeloma (MM) and its correlation with clinical parameters. Methods: Thirteen participants (9 males, 4 females; median age 65 years) with MM were recruited in this prospective observational study. Six participants were included for staging evaluation, seven were included for follow-up evaluation and underwent Ga-68 Pentixafor PET/CT. Focal PET-positive bone marrow lesions or diffuse bone marrow uptake (uptake more than liver) was considered a positive scan. Quantitative variables like SUVmax, SUVmean, total bone marrow volume and uptake (TBMV & TBMU) and tumor to background ratio (TBRmax) were obtained. Durie Salmon Plus Staging (DSPS) was used for MM staging by PET/CT and was compared with the International Staging System (ISS). Statistical comparison was performed between PET/CT quantitative variables and laboratory parameters. Results: Twelve participants (12/13) had positive Ga-68 Pentixafor PET/CT, among which one was diagnosed to have anaemia of chronic disease. One participant (1/13) who was clinically negative on follow-up had negative Ga-68 Pentixafor PET/CT. The sensitivity, specificity, PPV and NPV of Ga-68 Pentixafor PET/CT in MM (95% CI) was observed to be 100%, 50%, 91.6% and 100%, respectively. The correlation between DSPS and ISS in the patients who came for staging scans was found to be statistically significant (p-value 0.02). In quantitative analysis, either of the quantitative variables in Ga-68 Pentixafor PET/CT was positively correlated with clinical parameters related to tumor burden like CRAB score, Serum Protein Electrophoresis M-protein, beta 2 microglobulin, LDH, percentage of plasma cells infiltrates in bone marrow aspiration, ISS, serum free light chain and negatively correlated with haemoglobin, albumin (p-value < 0.5). Conclusion: Ga-68 Pentixafor PET/CT is a promising tracer and the only available non-invasive tool to assess the whole-body disease burden of CXCR4 receptors in staging and follow-up of MM. In addition, it has a vital role in the development of CXCR4-targeted theranostics. Dual tracer imaging using F-18 FDG and Ga-68 Pentixafor PET/CT may help in evaluating tumor heterogeneity in MM and add prognostic value at diagnosis and follow-up.

Article activity feed